Table 1

Clinical features of participants

Asymptomatic hyperuricaemia (n=25)Gout (n=33)
Age, years64 (13)61 (15)
Male sex, n (%)22 (88%)28 (85%)
Ethnicity, n (%)18 European21 European
3 Asian17 Pacific
2 Māori4 Māori
2 Pacific1 Asian
Gout disease duration, yearsNA11 (10)
Gout flare frequency in the preceding 3 monthsNA1.8 (4.0)
Chronic kidney disease5 (20%)19 (58%)
Ischaemic heart disease6 (24%)9 (27%)
Heart failure4 (16%)10 (30%)
Diuretic use, n (%)12 (48%)14 (42%)
Urate-lowering therapy*, n (%)0 (0%)27 (82%)
Duration of urate-lowering therapy, monthsNA34 (27)
BMI, kg/m232.0 (5.7)35.0 (8.3)
Serum urate590 (60) µmol/L430 (12) µmol/L
9.8 (1.0) mg/dL7.2 (2.0) mg/dL
Serum creatinine, µmol/L98 (23)144 (131)
  • Unless specified, data are presented as mean (SD).

  • *Includes allopurinol and probenecid.

  • BMI, body mass index.